Genenta Science S.p.A annual free cash flow
2020
2021
2022
2023
2024
2025
Genenta Science S.p.A reported −€6.9M in free cash flow for fiscal 2025, a decrease of €630,942 from the previous fiscal year.
View full Genenta Science S.p.A company overview| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −€6.9M | −€630,942 | — | — |
| 2024 | 2024-12-31 | −€6.2M | €5.0M | — | — |
| 2023 | 2023-12-31 | −€11.2M | −€3.8M | — | — |
| 2022 | 2022-12-31 | −€7.4M | −€478,123 | — | — |
| 2021 | 2021-12-31 | −€7.0M | −€901,731 | — | — |
| 2020 | 2020-12-31 | −€6.1M | — | — | — |
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|
Over the last five reported fiscal years, free cash flow declined from −€6.1M to −€6.9M, a net decrease of €810,132.
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Genenta Science S.p.A filings at SEC.gov ↗